002022.SZ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Stats
Today's Volume	4.72M
Average Volume	4.09M
Market Cap	4.77B
EPS	CNY-0.480 ( 2022-12-31 )
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-19.72
ATR14	CNY0.0100 (0.11%)

Volume Correlation

Long: 0.53 (weak)

Short: 0.58 (weak)

Signal:(48.539) Neutral

Shanghai Kehua Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shanghai Kehua Correlation - Currency/Commodity

0.31
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.38
( neutral )

0.00
( neutral )

0.19
( neutral )

Shanghai Kehua Financials

Annual	2022
Revenue:	CNY6.97B
Gross Profit:	CNY3.66B (52.56 %)
EPS:	CNY3.37

Q3	2023
Revenue:	CNY507.75M
Gross Profit:	CNY211.80M (41.71 %)
EPS:	CNY-0.0798

Q2	2023
Revenue:	CNY563.33M
Gross Profit:	CNY243.08M (43.15 %)
EPS:	CNY-0.0654

Q1	2023
Revenue:	CNY833.15M
Gross Profit:	CNY390.60M (46.88 %)
EPS:	CNY0.190

Shanghai Kehua

Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.